Streetbeat News

Revenues

PBLA

Panbela Therapeutics Inc. has announced the publication of a clinical study of DFMO, an investigational drug for cancer treatment, in the British Journal of Cancer. The study's findings support the potential of DFMO as a therapeutic option for patients with pancreatic cancer. This publication could positively influence the perception of Panbela's research and development efforts in the oncology field.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:16 pm

NVEI

Nuvei Corporation (NASDAQ:NVEI) has announced a partnership with Euroairlines to process transactions and support the airline's growth. Nuvei will handle direct and indirect traffic payments for Euroairlines globally, including the launch of a new online B2B2C portal allowing direct sales of flight tickets. The partnership is expected to enhance Euroairlines' payment processing in the US, Europe, and Latin America and add new revenue streams. Nuvei's collaboration with UATP will also process indirect traffic through UATP One Merchant Services.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:14 pm

BNRG

Brenmiller Energy Ltd. (NASDAQ:BNRG) has received a $450,000 grant from the Israel Innovation Authority for its thermal energy storage project at Wolfson Hospital in Israel. This grant complements a previously approved $3.7 million budget from the Israel Ministry of Finance. The bGen™ ZERO system by Brenmiller is expected to save Wolfson Hospital up to $1.3 million annually and reduce its carbon footprint by 3,900 tons per year. The company has also received a grant from the Israel Ministry of Environmental Protection for a project at a beverage plant owned by Tempo Beverages Ltd., a subsidiary of Heineken International B.V. Brenmiller's bGen™ ZERO system, named among TIME's Best Inventions of 2023, is designed to convert electricity into heat for industrial processes and support utility-scale renewable energy projects.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:14 pm

DMTK

DermTech has announced the topline results from a study evaluating its melanoma test, which showed a negative predictive value higher than 99% across all skin types. This indicates the test's high accuracy in correctly identifying individuals who do not have melanoma.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:06 pm

BHC

Bausch Health Companies Inc. and its subsidiary Solta Medical announced that China's National Medical Products Administration (NMPA) has approved Thermage FLX and the TR-4 Return Pad for use in China. This approval is a significant milestone for Solta Medical, expanding their business and showcasing the success of their R&D and Regulatory Teams. Thermage is a non-invasive skin treatment that has been performed over two million times globally. The approval allows Solta Medical to continue growing the Thermage brand in China, building on the success of Thermage CPT since 2015. The article also provides indications for the use of Thermage systems and important safety information for potential patients.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:06 pm

LPCN

Lipocine Inc. (LPCN) has entered into an exclusive licensing agreement with Verity Pharmaceuticals for the U.S. and Canadian rights to market TLANDO, an oral testosterone replacement therapy (TRT). Lipocine will receive an $11 million license fee and up to $259 million in development and commercial sales milestones, plus royalties up to 18% on net sales. The commercialization of TLANDO in the U.S. will transition to Verity Pharma on Feb. 1, 2024. Lipocine retains rights outside the U.S. and Canada and non-TRT rights globally. The deal aligns with Lipocine's focus on CNS disorders and adds value to its non-core assets.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 1:03 pm

PSTG

Analysts have provided mixed evaluations for Pure Storage (NYSE:PSTG) with 2 bullish and 4 somewhat bullish ratings. The average 12-month price target is $40.5, down from the previous $43.00. Keybanc's Thomas Blakey raised the target to $43.00, while others like Raymond James and JP Morgan lowered their targets. Pure Storage's financial performance is strong, with a 12.84% revenue growth, a 9.23% net margin, and a 6.59% ROE. The company's market cap is below industry benchmarks, but it has a low debt-to-equity ratio of 0.24.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 1:01 pm

EGHT

Analysts have recently updated their ratings and price targets for 8x8 Inc (NASDAQ:EGHT), with a mix of bullish and indifferent stances. Over the last three months, 4 analysts have issued ratings, with 3 bullish and 1 indifferent. The average 12-month price target is now $4.00, down from $4.75, with a high estimate of $5.00 and a low of $2.50. Analysts from Rosenblatt, Barclays, Craig-Hallum, and Needham have adjusted their price targets, reflecting changes in market conditions and company performance. 8x8's financial overview shows a decline in revenue growth, a high debt-to-equity ratio, but strong net margin, ROE, and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 1:00 pm

NET

Over the past three months, 5 analysts have provided diverse ratings for Cloudflare (NYSE:NET), with recent updates showing a mix of 'Overweight', 'Equal-Weight', and 'Neutral' stances. The average 12-month price target for NET is now $66.8, up from $60.40, with a high estimate of $94.00 and a low of $55.00. Key analysts from firms like Keybanc and Morgan Stanley have adjusted their price targets and ratings, reflecting their latest views on the company's performance. Cloudflare's financials show a market cap above industry averages, a revenue growth rate of 32.2%, a net margin of -7.01%, an ROE of -3.51%, an ROA of -0.92%, and a debt-to-equity ratio of 2.03.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 1:00 pm

FFIV

Analysts have provided mixed reviews on F5 (NASDAQ:FFIV) over the last three months, with 6 different ratings ranging from bullish to bearish. The average 12-month price target is $174.67, down from $176.50, with a high of $204.00 and a low of $160.00. Key analysts from firms like Keybanc, B of A Securities, and RBC Capital have adjusted their ratings and price targets, reflecting their views on the company's market dynamics and performance. F5 is a leader in application delivery controllers, with a focus on security, performance, and automation, and has shown positive revenue growth and strong financial health indicators such as net margin and ROE.

Portfolio Pulse from Benzinga Insights

January 18, 2024 | 1:00 pm